Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4858187 | 0.99 | ACHE (0.54) | ACHENPC1TTRL3MBTL1LMNA | |
| SCHEMBL6035083 | 0.99 | ACHE (0.54) | ACHENPC1TTRL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL4859731 | 0.98 | ACHE (0.54) | ACHENPC1TTRL3MBTL1LMNA | |
| SCHEMBL13987332 | 0.95 | ACHE (0.56) | ACHENPC1TTRL3MBTL1KMT2A | |
| SCHEMBL13987347 | 0.94 | ACHE (0.55) | ACHENPC1TTRL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL4913701 | 0.94 | ACHE (0.55) | ACHENPC1TTRL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL4853674 | 0.94 | ACHE (0.54) | ACHENPC1TTRL3MBTL1KMT2A | |
| SCHEMBL13987265 | 0.90 | ACHE (0.55) | ACHEL3MBTL1 | |
| SCHEMBL6034302 | 0.89 | ACHE (0.58) | ACHENPC1TTRLMNATP53 | |
| Hydrochloric Acid SCHEMBL4859088 | 0.89 | ACHE (0.54) | ACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | ACHE 1/4885NPC1 1160/4885TTR 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.